Ignite Creation Date:
2025-12-25 @ 4:38 AM
Ignite Modification Date:
2026-03-01 @ 6:11 AM
Study NCT ID:
NCT02810418
Status:
COMPLETED
Last Update Posted:
2022-03-15
First Post:
2016-06-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08-03
Start Date Type:
ACTUAL
Primary Completion Date:
2019-01-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-22
Completion Date Type:
ACTUAL
First Submit Date:
2016-06-22
First Submit QC Date:
None
Study First Post Date:
2016-06-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-12-15
Results First Submit QC Date:
None
Results First Post Date:
2021-02-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-16
Last Update Post Date:
2022-03-15
Last Update Post Date Type:
ACTUAL